Platform A · Bi-enzymatic oral tablet · Nutraceutical and pharma path

EquiHista®

Degrade histamine at the source.

Plant-derived diamine oxidase (DAO) paired with catalase in a gastro-resistant tablet. DAO breaks down dietary histamine in the gut; catalase removes the hydrogen peroxide DAO releases, so the enzyme keeps working.

Granted US and European patents GRAS study underway Comparative study · Feb to Mar 2027
Become a partner See the mechanism

The bi-enzymatic cycle

DAO degrades · Catalase recycles

Histamine + O₂ + H₂O Aldehyde + H₂O₂ + NH₃ DAO Catalase 2 H₂O₂ → 2 H₂O + O₂

Protected by two granted patents

EquiHista® is the product built on Histapharm's first two patents.

United States Granted 30 Jan 2018

US 9,878,020 B2

Oral enzyme compositions for intestinal delivery

Covers DAO and catalase formulated for oral delivery to the intestine. Assignee: Histapharm Inc., Longueuil, Quebec, Canada. Inventors include Dr Mircea Alexandru Mateescu and Dr Pompilia Ispas-Szabo.

Europe Granted

EP 2 694 098 B1

European counterpart of the US patent

Granted by the European Patent Office (EPO), the patent authority for its member states, extending the same oral DAO and catalase technology to Europe.

The role

Support for people who cannot clear dietary histamine.

In histamine intolerance, the gut's own DAO enzyme is too low to break down the histamine in food such as aged cheese, cured meat, wine or fish. EquiHista® supplies a plant DAO, protected by catalase, exactly where that histamine arrives: in the intestine, before it is absorbed.

01

Acts in the gut

Degrades histamine locally, before it reaches the bloodstream.

02

Removes, rather than blocks

Antihistamines block receptors and leave histamine in place. EquiHista® breaks the molecule down.

03

Taken with meals

An oral tablet timed to meet histamine as food enters the intestine.

The mechanism

Two enzymes. One closed loop.

DAO uses oxygen and water to degrade histamine and releases hydrogen peroxide, which damages DAO itself and the gut lining. Catalase turns that peroxide back into oxygen and water: the very inputs DAO needs next.

01

Gastro-resistant passage

The tablet's protective matrix carries both enzymes intact through stomach acid.

02

DAO degrades histamine

Released in the intestine, plant DAO breaks histamine down:

histamine + O2 + H2O → aldehyde + H2O2 + NH3

03

Catalase clears the peroxide

Hydrogen peroxide is neutralised as fast as it forms:

2 H2O2 → 2 H2O + O2

04

DAO keeps working

Freed from its own by-product, DAO stays active longer and degrades more histamine per dose.

Advantages

What a DAO-only supplement cannot do.

Catalase protects DAO

Hydrogen peroxide inactivates DAO as it works. Catalase removes it, so the enzyme lasts through intestinal transit.

Gentler on the gut lining

In the inventors' 2017 study on human intestinal (Caco-2) cells, adding catalase to plant DAO reduced the damage linked to peroxide.

More effect per milligram

If catalase multiplies DAO's output, the same result needs less DAO, lowering cost per dose. The 2027 study measures that factor.

Gastro-resistant tablet

A tablet format, in a market dominated by capsules, with a matrix designed to release the enzymes past the stomach.

Plant-derived, vegan

DAO from legume (pea) seedlings, with no porcine kidney extract, the traditional animal source of DAO.

Patent-protected pairing

The oral DAO and catalase composition is covered by granted US and European patents held by Histapharm.

February to March 2027 · Comparative efficacy study

EquiHista® against the market's DAO-only products.

A six-arm in vitro study benchmarks the DAO + catalase formula against DAO-only supplements on the market, with 60,000 HDU as the reference dose. HDU, histamine degrading units, is the industry's measure of DAO activity.

Conditions

Simulated intestinal fluid, pH 6.8, 37 °C, per the US Pharmacopeia (USP) method

Time points

0, 15, 30, 60, 120 and 180 minutes, the realistic small-intestine transit window

ArmDAO dose (HDU)CatalaseWhat it shows
A
60,000
No Market reference, DAO only
B
60,000
Yes EquiHista® at equal dose: the catalase factor
C
30,000
Yes Same effect at half the DAO?
D
15,000
Yes Same effect at a quarter of the DAO?
E
0
Yes Control: catalase alone
F
0
No Control: spontaneous breakdown

Measured

Histamine remaining, hydrogen peroxide accumulated, and residual DAO activity, in every arm, at every time point.

Result 1 · the k factor

How many times more histamine DAO degrades when catalase is present, at the same HDU dose.

Result 2 · equivalent dose

The lowest EquiHista® dose that matches 60,000 HDU of DAO alone at 120 minutes.

Interactive simulatorRun EquiHista® against any DAO-only supplement Try it below

Interactive simulator

EquiHista® against any DAO-only supplement, with your own numbers.

Enter any DAO supplement on the market from its label and run it against EquiHista®, the patented DAO + catalase tablet, on the same histamine-rich meal. The comparison rests on declared DAO activity (HDU), so it holds whatever the competitor's DAO source, format or other ingredients. The model tracks how much histamine each one degrades before its DAO is worn out by the hydrogen peroxide it produces.

DAO-only competitor

Any DAO supplement without catalase: animal or plant DAO, capsule or tablet, with or without other ingredients. Enter it from its label.

EquiHista®

Plant DAO with catalase as the engine; gastro-resistant, modelled as fully delivered

The meal

FormulaHistamine degradedDAO left at endPeak H₂O₂
DAO-only competitor{{d0}}{{e0}}{{h0}}
EquiHista®{{d1}}{{e1}}{{h1}}

{{headA}}

Histamine remaining

mg left in the gut

{{y1a}}{{y1b}}{{y1c}}{{y1d}}0 0 min{{xMid}}{{xEnd}}

Active DAO

% of the dose still working

100%75%50%25%0 0 min{{xMid}}{{xEnd}}

More capsules, diminishing return

Histamine degraded (mg) by the same number of capsules or tablets of each

{{y1a}}{{y1b}}{{y1c}}{{y1d}}0 123456

Against the whole DAO-only market

Capsules of a DAO-only product needed to match {{hCapsTxt}} of EquiHista®, at each common label dose. Same meal and gut settings as above.

DAO per capsuleDegraded by 1 capsuleCapsules to match
5,000 HDU{{m1d}}{{m1n}}
10,000 HDU{{m2d}}{{m2n}}
20,000 HDU{{m3d}}{{m3n}}
30,000 HDU{{m4d}}{{m4n}}
60,000 HDU{{m5d}}{{m5n}}
Your competitor · {{sHduTxt}}{{mYd}}{{mYn}}
DAO-only competitor EquiHista®

Model, not clinical data. Competitor figures are whatever you enter from its label. The model counts only the DAO activity the label declares in HDU; the competitor's DAO source, coating and other ingredients enter only through the share of DAO reaching the intestine active, set by you. Kinetics: DAO with oxygen dependence, catalase removal of hydrogen peroxide, DAO inactivation by peroxide, 200 mL gut volume and the oxygen level set above. In the colon there is almost no oxygen, so DAO hardly works and survives for that reason, with or without catalase. Constants are illustrative until the February to March 2027 study replaces them with bench data.

HISTAPHARM EquiHista ® DAO + CATALASE Bi-enzymatic tablets GASTRO-RESISTANT

The product

Bottled, and soon ready for market launch.

EquiHista® will come as a finished, patent-protected tablet in a retail bottle, or be licensed to a partner to take to pharmacies, retail and direct-to-consumer channels under a licence or supply agreement.

Plant DAO + catalase in one gastro-resistant tablet
Nutraceutical route first, with a pharma path open
Partner branding, territory and supply terms negotiable
GRAS study underwayA GRAS (Generally Recognized As Safe) safety assessment, the US Food and Drug Administration's pathway for food ingredients, is in progress for the US market.
EU path as a food supplementFor the European Union, EquiHista® follows the food supplement route under the EU Food Supplements Directive (2002/46/EC), with novel food status reviewed under Regulation (EU) 2015/2283.

Open for partnership

The partnership gate is open.

Histapharm is reviewing partnership proposals for EquiHista®: licensing, supply and co-development, by territory or worldwide. A full acquisition of the asset will also be considered, at the right valuation.

Full detailshistapharm.com Under NDAVirtual Data Room For more, contactmikeb@histapharm.com

Mike Baron, VP, Business Development & Co-Founder · Histapharm Inc., Longueuil, Quebec, Canada